Federico Conrotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Federico Conrotto has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Fabrizio D’ Ascenzo
Department of Medical Sciences, University of Turin, Turin, Italy
4 shared publications - Fiorenzo Gaita
Department of Medical Sciences, University of Turin, Turin, Italy
2 shared publications - Ovidio De Filippo
Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Turin, Italy
2 shared publications Pierluigi Omedè
Division of Cardiology, Cardiovascular and Thoracic Department, University of Turin, Città Della Salute e della Scienza, Turin, Italy
2 shared publications- Alessandro Depaoli
University Radiodiagnostic Unit, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy
1 shared publication - Alessandro Serafini
Departement of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Transcatheter Aortic Valve Implantation for Pure Native Aortic Regurgitation: A Comprehensive State-of-the-Art Review
Pure native aortic regurgitation (AR) remains a challenging and frequently undertreated valvular disease, associated with substantial morbidity and mortality. Surgical aortic valve repair or replacement remains the standard of care; however, many patients are older, frail, or at prohibitive surgical risk, creating an unmet need for less invasive therapeutic options. In this context, transcatheter aortic valve implantation (TAVI) has progressively emerged as a potential alternative. However, the application of TAVI in AR has historically been limited by the absence of annular and leaflet calcification, the presence of large and often noncircular annuli, and the resulting risks of transcatheter valve embolization or migration, residual paravalvular regurgitation, and conduction disturbances. This review summarizes contemporary evidence on TAVI for pure native AR, spanning early off-label experience with first-generation self-expanding and balloon-expandable valves to newer-generation platforms and dedicated devices. Recent observational studies and multicenter registries have shown meaningful improvements in procedural success, lower rates of residual AR and second valve implantation, and acceptable short- and mid-term mortality with contemporary off-label devices. Dedicated systems, including JenaValve Trilogy, J-Valve, and others, have further enhanced anchoring and sealing performance, achieving markedly lower rates of valve migration and significant residual regurgitation. Nonetheless, permanent pacemaker implantation remains a major limitation for several platforms. In parallel, the AURORA trial introduced an anatomy-guided strategy based on multidetector computed tomography classification and dual anchoring theory, suggesting that careful anatomical selection and optimized implantation planning may improve outcomes even with non-dedicated devices. Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting. Future progress will likely depend on further refinement of dedicated devices, reduction of conduction-related complications, and broader integration of patient-specific anatomical and biomechanical assessment to optimize device selection and implantation strategy.
- 22 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Open AccessTranscatheter Aortic Valve Implantation for Pure Native Aortic Regurgitation: A Comprehensive State-of-the-Art Review
Pure native aortic regurgitation (AR) remains a challenging and frequently undertreated valvular disease, associated with substantial morbidity and mortality. Surgical aortic valve repair or replacement remains the standard of care; however, many patients are older, frail, or at prohibitive surgical risk, creating an unmet need for less invasive therapeutic options. In this context, transcatheter aortic valve implantation (TAVI) has progressively emerged as a potential alternative. However, the application of TAVI in AR has historically been limited by the absence of annular and leaflet calcification, the presence of large and often noncircular annuli, and the resulting risks of transcatheter valve embolization or migration, residual paravalvular regurgitation, and conduction disturbances. This review summarizes contemporary evidence on TAVI for pure native AR, spanning early off-label experience with first-generation self-expanding and balloon-expandable valves to newer-generation platforms and dedicated devices. Recent observational studies and multicenter registries have shown meaningful improvements in procedural success, lower rates of residual AR and second valve implantation, and acceptable short- and mid-term mortality with contemporary off-label devices. Dedicated systems, including JenaValve Trilogy, J-Valve, and others, have further enhanced anchoring and sealing performance, achieving markedly lower rates of valve migration and significant residual regurgitation. Nonetheless, permanent pacemaker implantation remains a major limitation for several platforms. In parallel, the AURORA trial introduced an anatomy-guided strategy based on multidetector computed tomography classification and dual anchoring theory, suggesting that careful anatomical selection and optimized implantation planning may improve outcomes even with non-dedicated devices. Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting. Future progress will likely depend on further refinement of dedicated devices, reduction of conduction-related complications, and broader integration of patient-specific anatomical and biomechanical assessment to optimize device selection and implantation strategy.
- 1 July 2021
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 14 (13) , e157-e159
“Pressure Pressing Down on Me”
- 1 July 2021
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 14 (13) , e157-e159
“Pressure Pressing Down on Me”
- 1 July 2017
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 18 (5) , 367-368
Left main occlusion secondary to infective endocarditis vegetation: “The unusual suspect”
- 1 July 2017
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 18 (5) , 367-368
Left main occlusion secondary to infective endocarditis vegetation: “The unusual suspect”
- Open Access
- 13 October 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-13
The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis
Objective. Negative results of recent randomized clinical trials testing the hypothesis of target therapy for patients with high on-treatment platelet reactivity (HOPR) have questioned its independent impact on clinical outcomes. 26 studies with 28.178 patients were included, with a median age of 66.8 (64–68) and 22.7% (22.4–27.8), of female gender. After a median follow-up of 1 year (0.1–1), cardiac adverse events occurred in 8.3% (3–11; all results are reported as median and interquartile range) of patients. Pooling all studies together, on-treatment platelet reactivity significantly increased the risk of adverse events (OR 1.33 [1.09, 1.64],). However, a sensitivity analysis showed that HOPR did not increase the risk of adverse events for patients with ACS, AMI, or stable angina as well as patients resistant to aspirin, ADP antagonists, or both. For all studies, publication bias was formally evident; after adjusting for this, HOPR did not significantly increase adverse cardiac events (OR 1.1 : 0.89–1.22,0%).Conclusions. After adjusting for clinical confounders (like risk factors and clinical presentation) and for relevant publication bias, HOPR was not an independent prognostic indicator in unselected patients with both stable and unstable coronary disease for an adverse cardiac event. The clinical importance of HOPR for high-risk populations remains to be assessed.- 13 October 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-13
Open AccessThe Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis
Objective. Negative results of recent randomized clinical trials testing the hypothesis of target therapy for patients with high on-treatment platelet reactivity (HOPR) have questioned its independent impact on clinical outcomes. 26 studies with 28.178 patients were included, with a median age of 66.8 (64–68) and 22.7% (22.4–27.8), of female gender. After a median follow-up of 1 year (0.1–1), cardiac adverse events occurred in 8.3% (3–11; all results are reported as median and interquartile range) of patients. Pooling all studies together, on-treatment platelet reactivity significantly increased the risk of adverse events (OR 1.33 [1.09, 1.64],). However, a sensitivity analysis showed that HOPR did not increase the risk of adverse events for patients with ACS, AMI, or stable angina as well as patients resistant to aspirin, ADP antagonists, or both. For all studies, publication bias was formally evident; after adjusting for this, HOPR did not significantly increase adverse cardiac events (OR 1.1 : 0.89–1.22,0%).Conclusions. After adjusting for clinical confounders (like risk factors and clinical presentation) and for relevant publication bias, HOPR was not an independent prognostic indicator in unselected patients with both stable and unstable coronary disease for an adverse cardiac event. The clinical importance of HOPR for high-risk populations remains to be assessed.